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Abstract The majority of endometrial carcinomas are classi-
fied as Type I endometrioid endometrial carcinomas (EECs) and
have a good prognosis. Type II non-endometrioid endometrial
carcinomas (NEECs) have a significant worse outcome. Yet,
20 % of the EECs are associated with an unexplained poor
outcome. The aim of this study was to determine if L1CAM
expression, a recently reported biomarker for aggressive tumor
behavior in endometrial carcinoma, was associated with clinico-
pathological features of EECs. A total of 103 patients diagnosed
as EEC at the RadboudUniversityMedical Centre, based on the
pathology report were selected. L1CAM status of these tumors
was determined, and histologic slides were reviewed by two
expert pathologists. L1CAM-positivity was observed in 17 %
(18/103). Review of the diagnostic slides revealed that 11 out of
these 18 L1CAM-positive tumors (61 %) contained a serous- or
mixed carcinoma component that was not initially mentioned in
the pathology report. L1CAM-expression was associated with
advanced age, poor tumor grade, and lymphovascular space
invasion. A worse five year progression free survival rate was
observed for patients with L1CAM-positive tumors (55.6 % for
the L1CAM-positive group, compared to 83.3 % for the
L1CAM-negative group P = 0.01). L1CAM expression carries
prognostic value for histologically classified EEC and supports
the identification of tumors with a NEEC component.
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Introduction
Endometrial carcinoma is the most common gynecological
malignancy in industrialized nations [1]. The majority of en-
dometrial carcinomas is classified as type I endometrioid en-
dometrial carcinoma (EEC) and has a good prognosis in gen-
eral. Type II carcinoma represents non-endometrioid endome-
trial carcinoma (NEEC), and carries a high risk of disease
progression. Type I carcinomas are characterized as diploid
tumors, with estrogen-, and progesterone receptors, PTEN al-
terations, microsatellite instability, mutations of K-RAS, and
CTNNB1. Type II carcinomas on the contrary, are often aneu-
ploid, and show over expression of P53 and Her2/neu [2, 3].
Yet, about 20 % of the individual cases does not fit within this
dualistic model: EECs with poor clinical outcome [3, 4]. This
group of endometrial carcinomas are either misclassified
based on their histological appearance, or are inherently
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different despite truly morphological and clinical characteris-
tics of EEC.
Recently, expression of L1 cell adhesion molecule
(L1CAM) has been associated with aggressive subtypes of
endometrial carcinoma [5]. Moreover, L1CAM has shown to
be of great importance for the prediction of clinical outcome in
FIGO-stage I, histologically confirmed EECs [6]. L1CAM is a
member of the immunoglobulin super family, and a neural cell
recognition molecule, implicated in embryonic brain develop-
ment [7]. L1CAM has an important role in the regulation of
cell-cell interactions in neurohistogenesis, including axon out-
growth, neuronal migration, and regeneration after trauma [6].
In carcinoma cell lines, L1CAM-expression augments cell
motility and tumor growth.
The current study was conducted in order to identify the
clinicopathological features of L1CAM-positive EECs, and to
confirm prognostic value of L1CAM in EEC patients.
Materials & Methods
Patients and Tissue Specimen
The nationwide network and registry of histo- and cytopathol-
ogy in the Netherlands (Pathologisch Anatomisch Landelijk
Geautomatiseerd Archief: PALGA) was used to search for pa-
tients diagnosed, and surgically treated with hysterectomy and
bilateral oophorectomy at the Radboud University Medical
Centre Nijmegen for EEC’s. The terms Buterus^ and
Bendometrioid carcinoma^ were used to search through the
PALGA database. Clinical data were collected by studying
the medical charts. Age, menopausal state, body mass index
(BMI), parity, use of estrogen, treatment, stage of disease, date
of recurrence of disease, date of death, and the cause of death
were registered. In case of missing values the case was not used
for the specific calculations. Stage of disease was based on the
2009 International Federation of Gynecology and Obstetrics
(FIGO) staging system. Four to eight representative slides of
all patients were retrieved from the pathology archive and used
for review. Review was done systematically including the fol-
lowing items: tumor grade, depth of myometrial invasion, the
presence of lymphovascular space invasion, and the histologi-
cal type. Review was performed independently by an experi-
enced pathologist (RM) and an expert gyneco-pathologist (JB),
who were unaware of the original pathology report, and the
clinical outcome of the patient. Initial diagnosis was compared
with the diagnosis after review. In case of discrepancy, the final
diagnosis was obtained by consensus between the two pathol-
ogists. Confirmed EECs were also included in the study of
Zeimet et al. [6] Immunohistochemical analysis of L1CAM
was performed on sections of all endometrial carcinomas. The
stained sections were analyzed by an independent pathologist
who was not aware of the clinical outcome of the patients.
Antibodies and Immunohistochemistry
A monoclonal antibody to L1CAM (L1-40.10) was obtained
after immunization of mice with human L1-Fc protein
Table 1 Clinical and pathologic characteristics (after review) in the
total population (n = 103)
Clinico-pathologic characteristics Total (n = 103)
Median age in years (range) 63 (24–86)
Postmenopausal
No 22 (21.3 %)
Yes 73 (70.9 %)
Unknown 8 (7.8 %)
Median BMI* in kg/m2 (range) 28.9 (18.7–53.6)
Lymph nodes
Positive 1 (1.0 %)
Negative 22 (21.3 %)
Unknown 80 (77.7 %)
Adjuvant radiotherapy
Yes 39 (37.9 %)
No 64 (62.1 %)
Adjuvant chemotherapy
Yes 1 (1.0 %)
No 102 (99.0 %)
FIGO stage**
Low (I-II) 84 (81.6 %)
High (III-IV) 19 (18.4 %)
Tumor grade
Low (1–2) 78 (75.7 %)
High (3) 25 (24.3 %)
Myometrial Invasion
< 50 % 61 (59.2 %)
> 50 % 42 (40.8 %)
Lymphovascular Space Invasion
Not present 80 (77.7 %)
Present 23 (22.3 %)
Histology
Endometrioid 92 (82.3 %)
Non- endometrioid 11 (10.7 %)
Adjuvant radiotherapy
No 64 (62.1 %)
Yes 39 (37.9 %)
Adjuvant chemotherapy
No 100 (99.0 %)
Yes 1 (1.0 %)
Five year disease specific survival rate 88.8 %
Five year progression free survival rate 77.7 %
Median follow up (months) (range) 57 (0–148)
*Body Mass Index
**1988 International Federation of Gynecology and Obstetrics staging
system
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comprising the ectodomain of L1. Staining was performed as
described previously [6]. Briefly, following EDTA antigen re-
trieval, sections were stained using the automated I6000
immunostainer (Biogenics, San Ramos, California, USA), stain-
ing of tissue was visualized using 3,3′-Diaminobenzidine
(Zymed lab. California, USA) as substrate, and counterstained
with Mayer’s haematoxylin. Positive staining was defined as
>10 % immunoreactivity in any section derived from the tumor.
Strong L1CAM expression in nerve bundles of deeper accom-
panying connective tissues was used as internal positive control.
Statistical Analysis
Differences in clinicopathological parameters between the
group of patients with L1CAM-positive and L1CAM-
negative tumors were tested for statistical significance using
the Pearson’s Chi-Square (χ2) test, or the Fisher’s exact test,
andMann-Whitney test. All P-values presented are two-sided,
and associations were considered significant if the P-value
was less than 0.05. Survival analyses were performed to study
the progression free survival (PFS). PFS was calculated from
the date of surgery until the last date of progression free fol-
low-up. The prognostic impact of clinicopathological param-
eters were analyzed by using univariable and multivariable
Cox proportional hazards models. The forward stepwise
method was used for selection procedures. These results were
expressed as hazard ratio’s (HR) with their 95 % confidence
intervals (95 % CI). All statistical analyses were performed
using the software package SPSS 20.0 (SPSS Inc).
Results
Patient Characteristics and Treatment
A total of 103 patients with EEC were selected for this study,
and included for analysis. Patient characteristics are presented
in Table 1. Lymph node dissection was performed only in
patients suspected of advanced stage and/non-endometrioid
histology according the Dutch guideline for endometrial can-
cer treatment.
Review of the Histological Slides
After review, the initial diagnosis was adjusted in 31 patients.
In 25 cases tumor grade changed. In 11 cases the histology
was classified different. Five tumors were finally diagnosed as
uterine papillary serous carcinoma (UPSC), three tumors
were diagnosed as mixed carcinoma, and three as undif-
ferentiated carcinomas. The diagnosis of mixed carcino-
ma was defined when at least 10 % of a second com-
ponent was present. The differences in initial diagnosis,
and diagnosis after review are shown in Supplemental
Digital Content Table 1.
Immunohistochemistry
L1CAM is positivity was particularly present, the cell mem-
branes of the tumor cells, and only weakly present in the
cytoplasm of these positive tumor cells. Neither stromal cells
Fig. 1 Endometrioid endometrial
carcinoma with L1-CAM positive
staining at the invasive front (a),
Papillary serous carcinoma with
L1-CAM positive staining (b),
Endometrioid carcinoma with L1-
CAM positive staining (c), Mixed
carcinoma with 50 %
endometrioid component and
50 % serous component, the
endometrioid component with
L1-CAM negative staining (d),
Mixed carcinoma with 50 %
endometrioid component and
50 % serous component, the
serous component with L1-CAM
positive staining (e),
Undifferentiated carcinoma with
L1-CAM positive staining (f)
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nor inflammatory cells were stained by L1CAM. In the study
population of 103 carcinomas, 18 patients showed
L1CAM-positive staining in the tumor (17 %). All cases
(n = 11) that were classified as NEEC after revision
were L1CAM positive (100 %), whereas only seven
cases of confirmed EECs were L1CAM-positive (7,6 %).
L1CAM staining showed variable intensity. Staining had a
tendency to more intensity at the invasive front (Fig. 1a).
The five tumors, diagnosed as pure UPSC after review of
the histological slides, showed L1CAM-expression through-
out a major part of the tumor specimens. A representative
example is shown in Fig. 1b. Figure 1c shows an ex-
ample of L1CAM-expression in EEC. In the two mixed
carcinomas with 50 % serous component, and 50 %
endometrioid component, the serous component was
strongly positive, whereas the endometrioid component
was weakly positive, or L1CAM-negative (Fig. 1d and e).
Figure 1f shows L1CAM-expression in an undifferentiated
carcinoma, which is diffuse positive trough the tumor
specimen.
L1CAM Expression and Clinicopathological
Characteristics
The clinicopathological characteristics of L1CAM-negative and
L1CAM-positive patients after review are summarized in
Table 2. Adjuvant treatment and time of follow up were equal
in both groups. Patients with L1CAM-negative tumors were sig-
nificantly younger compared to patients with L1CAM-positive
tumors. In addition, L1CAM-expression was associated with,
poor tumor grade (HR 3.80 (1.61–9.00)), and lymphovascular
space invasion (HR 4.13 (1.73–9.86)). Aworse five year progres-
sion free survival rate was observed for patients with L1CAM-
positive tumors (55.6 % for the L1CAM-positive group, com-
pared to 83.3 % for the L1CAM-negative group P = 0.01).
Discussion
This study was conducted to determine whether L1CAM-
expression in EECs is related to pathological features and
Table 2 Clinical and pathologic
characteristics (after review) in
the total population, the L1CAM-
negative- and the L1CAM-
positive tumours
Clinico-pathologic characteristics L1CAM-negative
n = 85
L1CAM-positive
n = 18
P-value
Mean age in years (range) 59.7 (24–86) 68.2 (47–81) <0.01
Postmenopausal
No 21 (26.3 %) 1 (6.7 %)
Yes 59 (73.7 %) 14 (93.3 %) 0.18
Median BMI in kg/m2 (range) 29.3 (18.7–53.6) 27.1 (19.8–47.1) 0.12
Lymph nodes
Positive 1 (5.6 %) 0 (27.8 %)
Negative 17 (94.4 %) 5 (100.0 %) 1.00
FIGO stage*
Low (I) 66 (77.6 %) 12 (66.7 %)
High (II-IV) 19 (22.4 %) 6 (33.3 %) 0.37
Tumor grade
Low (1–2) 75 (88.2 %) 3 (16.7 %)
High (3) 10 (11.8 %) 15 (83.3 %) <0.01
Myometrial Invasion
< 50 % 54 (63.5 %) 7 (38.9 %)
> 50 % 31 (36.5 %) 11 (61.1 %) 0.06
Lymphovascular Space Invasion
Not present 73 (85.9 %) 7 (38.9 %)
Present 12 (14.1 %) 11 (61.1 %) <0.01
Histology
Endometrioid 85 (100 %) 7 (38.9 %)
Non- endometrioid 0 (0.0 %) 11 (61.1 %) <0.01
Radiotherapy
No 49 (57.6 %) 13 (81.3 %)
Yes 36 (42.4 %) 3 (18.8 %) 0.10
Mean follow-up in months (range) 60.4 (0.4–148.0) 51.1 (0–147.0) 0.40
*2009 International Federation of Gynecology and Obstetrics staging system
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clinical outcome. Our study revealed L1CAM-expression in
18/103 (17 %) of the tumors originally diagnosed as EEC.
Eleven of these cases were reclassified as NEEC after expert
review of the original diagnostic slides, and seven L1CAM-
positive EECs were identified. These data illustrate that
L1CAM expression can be supportive for the identification
of NEEC.
The study group of 103 endometrial carcinoma patients is
representative for the population diagnosed with endometrial
cancer, with a median age at diagnosis of 63 years, a median
BMI of 28.9 kg/m2, a majority of early stage disease, and a
minority of poorly differentiated tumors. Yet, the study is lim-
ited by its relative low number of cases, and the retrospective
character of the study.
A recent multicenter study of L1CAM-expression in 1021
histologically confirmed EECs demonstrated L1CAM posi-
tivity in 17,7 % and demonstrated that L1CAM-expression
in EEC was an independent predictor of clinical outcome. A
small percentage of these cases showed areas of non-
endometrioid differentiation in less than 10 % of the tumor,
and this was associated with L1CAM-expression [6].
Interestingly, in the current study an equal percentage of
L1CAM positivity was initially observed, yet after revision
and reclassification L1CAM expression in EEC was observed
in 7,6 %. Our findings are in line with data of Bosse et al. who
observed a significantly lower percentage of L1CAM positiv-
ity in EEC [8]. The current study confirms that L1CAM-
expression carries prognostic value for histologically classi-
fied EEC, but also supports the identification of tumors with a
NEEC component. The recognition of UPSC can be challeng-
ing, and it is expected that improved awareness of the pathol-
ogist of the existence of UPSC nowadays, will decrease the
number of UPSCs mistaken for EECs.
Several studies have shown that L1CAM-expression is as-
sociated with aggressive carcinoma subtypes and tumor pro-
gression [9]. In serous ovarian and endometrial carcinomas,
L1CAM-expression is frequently present [9]. If L1CAM-
expression is present in EECs, it is associated with poor tumor
differentiation, absence of estrogen- and progesterone recep-
tors, and loss of E-cadherin expression [5]. In our study,
Fig. 2 Progression free survival in EEC patients compared with NEEC
patients in months (a), Disease specific survival in EEC patients
compared with NEEC patients in months (b), Progression free survival
in L1-CAM negative patients compared with L1-CAM positive patients
in months (c), Disease specific survival in L1-CAM negative patients
compared with L1-CAM positive patients in months (d)
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L1CAM-expression was associated with predictors of poor
clinical outcome like tumor grade and LVSI. As a conse-
quence, L1CAM expression was associated with a significant-
ly decreased 5-year progressive free survival. L1CAM expres-
sion was associated with recurrent disease, but not specific to
distant metastasis like previously published, but due to the
small numbers these results should be interpreted with caution
Fig. 2.
Currently, risk estimation in endometrial cancer is based on
both preoperative and postoperative factors. Data of the
MoMaTEC trial demonstrated that loss of hormone receptor
status in the preoperative tumor specimen was significantly
associated with lymph node metastasis [10].
In this pre-operative setting L1CAM could be a useful ad-
ditional tool. It not only helps to identify NEECs, but it also
identifies those EEC-patients who are at high risk of disease
progression.
Determination of histology in poorly differentiated tumors
can be challenging. Yet, accurate diagnosis of endometrial
carcinomas is of great clinical importance. In this study, the
mixed endometrial carcinomas showed L1CAM-expression
in the serous component, whereas the endometrioid compo-
nent was L1CAM-negative. These observations have been
described previously [5]. In literature, several immunohisto-
chemical markers are used to support the diagnosis of UPSC,
i.e. over-expression of p53, and p16, as well as loss of hor-
mone receptors. The current study demonstrates that L1CAM
might be a useful marker to distinguish EEC from NEEC. In
addition, L1CAM-staining was observed to be strongest at the
invasive front, which confirms the suggestion that L1CAM is
important for tumor invasion. However in the to date largest
reported study on L1CAM-expression in EEC, this particular
pattern of L1CAM-staining was not observed [6].
In conclusion, L1CAM is significantly associated with
non-endometrioid histology and other clinicopathological fac-
tors predicting poor survival. This makes L1CAM a potential
marker for pre-operative identification of patients needing ag-
gressive treatment. Furthermore, L1CAM could be a useful
marker in the detection of non-endometrioid histology and of
EEC with poor prognosis. A large prospective study is re-
quired to determine the clinical implications of L1CAM in
endometrial carcinomas.
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